Individualization of Tamoxifen Treatment for Breast Carcinoma

被引：29
作者：
Binkhorst, L. [1 ,2 ]
van Gelder, T. [2 ]
Mathijssen, R. H. J. [1 ]
机构：
[1] Erasmus Univ, Med Ctr, Daniel Den Hoed Canc Ctr, Dept Med Oncol, Rotterdam, Netherlands
[2] Erasmus Univ, Med Ctr, Dept Hosp Pharm, Rotterdam, Netherlands
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2012年 / 92卷 / 04期
关键词：
CYP2D6; GENOTYPE; EXPOSURE; WOMEN;
D O I：
10.1038/clpt.2012.94
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Traditionally, all patients treated with tamoxifen receive a standard dose. A number of studies claimed a clinically relevant impact of cytochrome P450 2D6 (CYP2D6) genotype on outcome, and therefore genotyping before tamoxifen therapy was advocated. Recent data showed that adequate exposure to the active metabolite endoxifen is important and that genotype only partially explains interindividual differences in endoxifen concentrations. Phenotyping approaches, as well as therapeutic drug monitoring (TDM) strategies, are now being tested to individualize tamoxifen treatment.
引用
收藏
页码：431 / 433
页数：3
相关论文
共 5 条
  • [1] Dextromethorphan As a Phenotyping Test to Predict Endoxifen Exposure in Patients on Tamoxifen Treatment
    de Graan, Anne-Joy M.
    Teunissen, Sebastiaan F.
    de Vos, Filip Y. F. L.
    Loos, Walter J.
    van Schaik, Ron H. N.
    de Jongh, Felix E.
    de Vos, Aad I.
    van Alphen, Robbert J.
    van der Holt, Bronno
    Verweij, Jaap
    Seynaeve, Caroline
    Beijnen, Jos H.
    Mathijssen, Ron H. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (24) : 3240 - 3246
  • [2] Genotype-Guided Tamoxifen Dosing Increases Active Metabolite Exposure in Women With Reduced CYP2D6 Metabolism: A Multicenter Study
    Irvin, William J., Jr.
    Walko, Christine M.
    Weck, Karen E.
    Ibrahim, Joseph G.
    Chiu, Wing K.
    Dees, E. Claire
    Moore, Susan G.
    Olajide, Oludamilola A.
    Graham, Mark L.
    Canale, Sean T.
    Raab, Rachel E.
    Corso, Steven W.
    Peppercorn, Jeffrey M.
    Anderson, Steven M.
    Friedman, Kenneth J.
    Ogburn, Evan T.
    Desta, Zeruesenay
    Flockhart, David A.
    McLeod, Howard L.
    Evans, James P.
    Carey, Lisa A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (24) : 3232 - 3239
  • [3] CYP2D6 Genotype as a Marker for Benefit of Adjuvant Tamoxifen in Postmenopausal Women: Lessons Learned
    Kelly, Catherine M.
    Pritchard, Kathleen I.
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2012, 104 (06) : 427 - 428
  • [4] Tamoxifen Metabolite Concentrations, CYP2D6 Genotype, and Breast Cancer Outcomes
    Madlensky, L.
    Natarajan, L.
    Tchu, S.
    Pu, M.
    Mortimer, J.
    Flatt, S. W.
    Nikoloff, D. M.
    Hillman, G.
    Fontecha, M. R.
    Lawrence, H. J.
    Parker, B. A.
    Wu, A. H. B.
    Pierce, J. P.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 (05) : 718 - 725
  • [5] Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma
    Muerdter, T. E.
    Schroth, W.
    Bacchus-Gerybadze, L.
    Winter, S.
    Heinkele, G.
    Simon, W.
    Fasching, P. A.
    Fehm, T.
    Eichelbaum, M.
    Schwab, M.
    Brauch, H.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 (05) : 708 - 717
1